HK1200176A1 - Human inding molecules capable of inding to and neutralizing influenza viruses and uses thereof - Google Patents

Human inding molecules capable of inding to and neutralizing influenza viruses and uses thereof

Info

Publication number
HK1200176A1
HK1200176A1 HK15100646.1A HK15100646A HK1200176A1 HK 1200176 A1 HK1200176 A1 HK 1200176A1 HK 15100646 A HK15100646 A HK 15100646A HK 1200176 A1 HK1200176 A1 HK 1200176A1
Authority
HK
Hong Kong
Prior art keywords
inding
human
influenza viruses
molecules capable
neutralizing influenza
Prior art date
Application number
HK15100646.1A
Other languages
English (en)
Chinese (zh)
Inventor
Theodorus Hendrikus Jacobus Kwaks
Ronald Vogels
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of HK1200176A1 publication Critical patent/HK1200176A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
HK15100646.1A 2012-03-08 2015-01-20 Human inding molecules capable of inding to and neutralizing influenza viruses and uses thereof HK1200176A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261608414P 2012-03-08 2012-03-08
EP12158525 2012-03-08
PCT/EP2013/054606 WO2013132007A1 (en) 2012-03-08 2013-03-07 Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof

Publications (1)

Publication Number Publication Date
HK1200176A1 true HK1200176A1 (en) 2015-07-31

Family

ID=49115966

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100646.1A HK1200176A1 (en) 2012-03-08 2015-01-20 Human inding molecules capable of inding to and neutralizing influenza viruses and uses thereof

Country Status (19)

Country Link
US (5) US8834881B2 (ko)
EP (1) EP2822968B1 (ko)
JP (1) JP6328061B2 (ko)
KR (1) KR102050615B1 (ko)
CN (2) CN104169298B (ko)
AR (1) AR091316A1 (ko)
AU (2) AU2013229488B2 (ko)
CA (1) CA2865594C (ko)
DK (1) DK2822968T3 (ko)
EA (1) EA028433B1 (ko)
ES (1) ES2664625T3 (ko)
HK (1) HK1200176A1 (ko)
MX (1) MX360056B (ko)
MY (1) MY170407A (ko)
NZ (1) NZ628382A (ko)
PH (2) PH12014501776B1 (ko)
SG (1) SG11201405226TA (ko)
TW (1) TWI628190B (ko)
WO (1) WO2013132007A1 (ko)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY170927A (en) 2011-11-28 2019-09-19 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
JP6371222B2 (ja) 2011-12-05 2018-08-08 トレリス バイオサイエンス リミテッド ライアビリティー カンパニー インフルエンザの受動免疫用抗体
NZ628382A (en) 2012-03-08 2017-03-31 Janssen Vaccines & Prevention Bv Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
CA2906676A1 (en) 2013-03-14 2014-09-25 Contrafect Corporation Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
EP2970397A2 (en) 2013-03-14 2016-01-20 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
ES2837392T3 (es) 2013-10-02 2021-06-30 Medimmune Llc Anticuerpos anti-influenza A neutralizantes y usos de los mismos
US20160304586A1 (en) * 2013-12-05 2016-10-20 Crucell Holland B.V. Process for preparing influenza vaccines
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
MX2016010059A (es) * 2014-02-04 2017-04-27 Contrafect Corp Anticuerpos útiles en la inmunización pasiva contra la gripe y composiciones, combinaciones y métodos para utilizarlos.
US9745365B2 (en) * 2014-03-27 2017-08-29 Genentech, Inc. Anti-influenza B virus hemagglutinin antibodies and methods of use
CA2954780A1 (en) * 2014-07-15 2016-01-21 Medimmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
TWI701258B (zh) 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
SG11201705614QA (en) 2015-02-05 2017-08-30 Janssen Vaccines & Prevention Bv Binding molecules directed against influenza hemagglutinin and uses thereof
KR20180002713A (ko) * 2015-05-11 2018-01-08 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 중화 펩티드 모방 화합물
WO2016200543A2 (en) * 2015-05-13 2016-12-15 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-inluenza antibodies and methods of use thereof
AU2016271323B2 (en) * 2015-06-01 2022-08-25 Medimmune, Llc Neutralizing anti-influenza binding molecules and uses thereof
US10696736B2 (en) 2015-06-03 2020-06-30 Xiamen University Broad-spectrum monoclonal anti-flu B antibody and uses thereof
JP2017062300A (ja) * 2015-09-24 2017-03-30 セイコーエプソン株式会社 半導体装置、システム、電子機器、及び、音声認識方法
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN116271017A (zh) 2016-01-13 2023-06-23 免疫医疗有限责任公司 治疗甲型流感的方法
WO2017148889A1 (en) 2016-03-01 2017-09-08 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza b neuraminidase
EA201990222A1 (ru) 2016-08-05 2019-07-31 МЕДИММЬЮН, ЭлЭлСи Антитела к o2 и пути их применения
CN109843917B (zh) 2016-10-19 2023-10-03 免疫医疗有限责任公司 抗o1抗体及其用途
AU2018229293A1 (en) 2017-02-28 2019-08-29 Janssen Biotech, Inc. Influenza vaccines based on AAV vectors
LT3589730T (lt) 2017-02-28 2024-03-12 The Trustees Of The University Of Pennsylvania Adenoasocijuoto viruso (aav) monofiletinės grupės f vektorius, ir jo panaudojimo būdai
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
CA3058567A1 (en) 2017-04-13 2018-10-18 Cadila Healthcare Limited Novel peptide based pcsk9 vaccine
CA3088194A1 (en) 2018-01-26 2019-08-01 Regeneron Pharmaceuticals, Inc. Human antibodies to influenza hemagglutinin
US20210147549A1 (en) * 2018-07-11 2021-05-20 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO PD-L1
EP3946613A1 (en) 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2021195326A1 (en) * 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
JP2023523336A (ja) 2020-04-27 2023-06-02 ツイスト バイオサイエンス コーポレーション コロナウイルス用の変異体核酸ライブラリー

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US6248780B1 (en) 1998-10-01 2001-06-19 Duquesne University Of The Holy Ghost Compounds for the treatment of estrogen-dependent illnesses and methods for making and using the same
PT1161548E (pt) 1999-04-15 2005-06-30 Crucell Holland Bv Producao de proteinas recombinantes numa celula humana utilizando sequencias codificando a proteina e1 de adenovirus
EP1402025B1 (en) 2001-06-15 2006-02-01 Crucell Holland B.V. Chimaeric phages
US7135174B2 (en) 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
EP2441471B1 (en) * 2005-03-08 2014-10-08 MedImmune, LLC Reassortant influenza viruses
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
BRPI0715141A2 (pt) 2006-08-03 2013-06-04 Astrazeneca Ab agente de ligaÇço alvejante, anticorpo isolado, fragmento de anticorpo isolado, molÉcula de Ácido nucleico, vetor, cÉlula hospedeira, mÉtodos para produzir um agente de ligaÇço alvejado, para produzir um anticorpo, para produzir um fragmento de anticorpo, para tratar um tumor maligno em um animal, para tratar inflamaÇço, e para inibir a interaÇço de alfabeta6 com seu ligando, e, conjugado
EP2450377A1 (en) 2006-09-07 2012-05-09 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
US8846867B2 (en) * 2007-06-26 2014-09-30 The Trustees Of The University Of Pennsylvania Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies
FR2921928B1 (fr) * 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
MX2011000768A (es) * 2008-07-25 2011-10-05 Inst Research In Biomedicine Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.
EP2179811B1 (en) 2008-10-21 2018-10-03 Agie Charmilles SA Method and apparatus for controlling an electric discharge machining process
PT2365828E (pt) * 2008-11-07 2014-12-12 Galaxy Biotech Llc Anticorpos monoclonais para o receptor 2 do factor de crescimento de fibroblastos
JP5780762B2 (ja) * 2008-12-25 2015-09-16 国立大学法人大阪大学 抗ヒトインフルエンザウイルス・ヒト型抗体
WO2010130636A1 (en) * 2009-05-11 2010-11-18 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
WO2010138564A1 (en) * 2009-05-26 2010-12-02 Mount Sinai School Of Medicine Of New York University Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
US9181328B2 (en) * 2012-01-31 2015-11-10 Osaka University Human monoclonal antibodies broadly protective against influenza B virus and methods of using the same
NZ628382A (en) 2012-03-08 2017-03-31 Janssen Vaccines & Prevention Bv Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof

Also Published As

Publication number Publication date
US20140341929A1 (en) 2014-11-20
AU2013229488B2 (en) 2017-12-07
TWI628190B (zh) 2018-07-01
US20160002318A1 (en) 2016-01-07
CA2865594C (en) 2021-07-27
PH12015502553A1 (en) 2017-04-10
US9200064B2 (en) 2015-12-01
NZ628382A (en) 2017-03-31
MX2014010755A (es) 2014-12-05
PH12015502553B1 (en) 2017-04-10
US20140065165A1 (en) 2014-03-06
US20130243792A1 (en) 2013-09-19
TW201339173A (zh) 2013-10-01
CN108640989B (zh) 2021-12-14
CN104169298A (zh) 2014-11-26
DK2822968T3 (en) 2018-04-16
KR20140135753A (ko) 2014-11-26
CN104169298B (zh) 2018-04-20
PH12014501776A1 (en) 2014-11-10
AU2013229488A1 (en) 2014-09-18
PH12014501776B1 (en) 2014-11-10
US8852595B2 (en) 2014-10-07
AU2018201647B2 (en) 2020-01-30
EP2822968A1 (en) 2015-01-14
WO2013132007A1 (en) 2013-09-12
AU2018201647A1 (en) 2018-03-29
AR091316A1 (es) 2015-01-28
NZ729856A (en) 2021-12-24
MX360056B (es) 2018-10-19
JP2015518369A (ja) 2015-07-02
US20150037345A1 (en) 2015-02-05
US8834881B2 (en) 2014-09-16
EP2822968B1 (en) 2018-01-10
EA201491656A1 (ru) 2014-12-30
JP6328061B2 (ja) 2018-05-23
CN108640989A (zh) 2018-10-12
EA028433B1 (ru) 2017-11-30
MY170407A (en) 2019-07-27
SG11201405226TA (en) 2014-11-27
CA2865594A1 (en) 2013-09-12
US9005621B2 (en) 2015-04-14
ES2664625T3 (es) 2018-04-20
KR102050615B1 (ko) 2019-11-29

Similar Documents

Publication Publication Date Title
HK1200176A1 (en) Human inding molecules capable of inding to and neutralizing influenza viruses and uses thereof
HK1202123A1 (en) Human antibodies to fel d1 and methods of use thereof fel d1
HK1213591A1 (zh) 生物粘合劑的製備和應用
HK1206037A1 (en) Human antibodies to gfr3 and methods of use thereof gfr3
EP2805287A4 (en) USE OF RECOGNITION OF HUMAN ENTRY TO PREVENT CONTAMINATION
ZA201501674B (en) Use of semaphorin-4d binding molecules to promote neurogenesis following stroke
GB201506561D0 (en) Treatment of amblyopia
PL2892556T3 (pl) Kompozycje i sposoby odnoszące się do leczenia chorób
ZA201501601B (en) Virus purification and formulation process
HK1201283A1 (en) Influenza c virus and vaccine
HUE036419T2 (hu) Légzõszervi depresszió kezelése
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
EP2751126A4 (en) USE OF HDL MOLECULES FOR THE TREATMENT AND PREVENTION OF PROINFLAMMATORY SUFFERING
GB201207907D0 (en) Treatment of depression
IL234446B (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
ZA201309304B (en) Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
ZA201203832B (en) Preparation and purification of iodixanol

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230305